Cargando…
Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report
BACKGROUND: Ulcerative colitis is a lifelong, immunologically mediated disease. Direct-acting antivirals (DAAs) are now available for the treatment of chronic hepatitis C virus (HCV) infection. An interferon-free regimen appears useful, safe and effective for many patients for whom interferon-based...
Autores principales: | Ohta, Yuki, Kanda, Tatsuo, Katsuno, Tatsuro, Yasui, Shin, Haga, Yuki, Sasaki, Reina, Nakamura, Masato, Wu, Shuang, Nakamoto, Shingo, Arai, Makoto, Yokosuka, Osamu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940930/ https://www.ncbi.nlm.nih.gov/pubmed/27401874 http://dx.doi.org/10.1186/s12876-016-0480-x |
Ejemplares similares
-
Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2017) -
Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin
por: Sasaki, Reina, et al.
Publicado: (2016) -
Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy
por: Nakamoto, Shingo, et al.
Publicado: (2015) -
Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype
por: Kanda, Tatsuo, et al.
Publicado: (2015) -
Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2016)